Cyril Amarchand Mangaldas represented MRG Group
The transaction reflects strategic collaboration in the region’s growing residential real estate market.
Cyril Amarchand Mangaldas
Cyril Amarchand Mangaldas Advises Vixar on Share Acquisition in The Belgian Waffle Co.
Cyril Amarchand Mangaldas advised Vixar on its acquisition of a shareholding in Bloombay Enterprises Private Limited, which operates The Belgian Waffle Co., one of India’s leading dessert-focused QSR brands with over 700 outlets across 250 cities.
Cyril Amarchand Mangaldas acted as legal counsels for KNR Constructions Limited on its sale of 4 roads assets to Indus Infra Trust for a consideration of INR 1543 Crores
The transaction involved the transfer of 100% shareholding through share purchase agreements, marking a key infrastructure asset monetisation deal.
Cyril Amarchand Mangaldas acted on proposed amalgamation of Orient Cement Limited with Ambuja Cements Limited
The merger involves equity issuance to Orient shareholders, cancellation of cross-holdings, and regulatory approvals, representing a key consolidation move in India’s cement and infrastructure sector.
Cyril Amarchand Mangaldas advised ICICI Prudential Asset Management Company Limited on its IPO aggregating to over ₹10,600 crores
The IPO, which saw over 39× subscription, marked a landmark transaction in India’s equity capital markets and commenced trading on the BSE and NSE on 19 December 2025.
Cyril Amarchand Mangaldas acted on proposed amalgamation of ACC Limited with Ambuja Cements Limited
The merger involves equity issuance by Ambuja to ACC shareholders and results in a post-merger change in Ambuja’s shareholding structure, marking a significant consolidation in India’s cement sector.
Cyril Amarchand Mangaldas acted as the transaction counsel in respect of issuance and allotment of non- convertible debentures of INR 3300 Crores by Vodafone Idea Telecom Infrastructure Limited
The transaction, India’s largest disclosed private credit deal in the telecom sector, was structured to support Vodafone Idea Limited’s capital expenditure and business growth.
Cyril Amarchand Mangaldas Advises Adani Enterprises on ₹24,930 Crores Rights Issue
The transaction was undertaken in compliance with SEBI ICDR Regulations and marks one of the largest rights issues in the Indian capital markets.
Cyril Amarchand Mangaldas is acting as Indian legal counsel to PTC Inc. on the sale of its Kepware and ThingWorx businesses
The transaction involves multidisciplinary legal advice spanning M&A, employment, tax, data privacy, and equity compensation matters.
Cyril Amarchand Mangaldas Advises Zenrock Chemicals and EAAA India Alternatives on Indo Borax Acquisition and Open Offer
The transaction resulted in a change of control and triggered a mandatory open offer under SEBI takeover regulations, alongside structured acquisition financing.
Cyril Amarchand Mangaldas Advises IFC on Nephrocare Health Services Limited IPO
The IPO comprised a fresh issue and an offer for sale, with IFC divesting part of its shareholding. Nephrocare’s equity shares were listed on Indian stock exchanges on 17 December 2025.
CAM advises Bhansali Productions and Sanjay Leela Bhansali on Strategic Partnership with Saregama
The transaction grants Saregama a significant minority equity stake in Bhansali Productions along with exclusive music rights for all future Bhansali films.
Cyril Amarchand Mangaldas represented Lighthouse Learning Private Limited and Mr. Prajodh Rajan (Founder and Group CEO) of Lighthouse Learning Private Limited.
The transaction strengthens Lighthouse Learning’s position as a leading Indian education services provider. CAM advised on corporate, diligence, real estate, employment, disputes, finance, and competition aspects of the deal.
Cyril Amarchand Mangaldas advises Larsen & Toubro Limited
The transaction marks the first phase of consolidating L&T’s real estate assets into a unified entity positioned for India’s growing property market.
Cyril Amarchand Mangaldas advises selling shareholders in the IPO of Meesho Limited
The firm advised prominent investors such as Elevation Capital, Peak Investments, Venture Highway, and Y Combinator. The issue opened on December 3 and closed on December 5, 2025.
Cyril Amarchand Mangaldas acted as the legal advisor to Sheela Foam Limited
Cyril Amarchand Mangaldas advised Sheela Foam Limited on further investment in Furlenco via preferential issue and structuring investor rights in the funding round.
Cyril Amarchand Mangaldas advises Serum Institute on sale of stake held in Biocon Biologics and subscription of shares in Biocon Limited, through share swap
Cyril Amarchand Mangaldas advised Serum Institute on the proposed sale of its stake in Biocon Biologics to Biocon and the simultaneous subscription of shares in Biocon Limited through a share swap transaction valued at ₹2,250 crore. The deal marks a significant restructuring in India’s biopharmaceutical sector.
Cyril Amarchand Mangaldas advised Ashoka Buildcon Limited on Macquarie’s exit from its group entities, Ashoka Concessions Limited and Jaora – Nayagaon Toll Road Company Private Limited
CAM advised Ashoka Buildcon Limited on Macquarie’s ~₹1,715 crore exit from its group entities, providing end-to-end transactional support on the divestment of stakes in Ashoka Concessions Limited and Jaora—Nayagaon Toll Road Company Private Limited.
Cyril Amarchand Mangaldas successfully represented Coinswitch in a domain name dispute concerning an impugned domain before the WIPO UDRP Panel
The Panel upheld Coinswitch’s claim on all three UDRP criteria, finding confusing similarity, lack of legitimate rights, and bad faith registration and use.
Cyril Amarchand Mangaldas acted as the Indian legal counsel to Sudeep Pharma Limited on the initial public offering of its equity shares.
Comprising a fresh issue and offer for sale by promoter shareholders. The IPO saw an exceptional overall subscription of 93.71 times, with QIB demand at 213.08 times.